by Duke-NUS Medical School Leukemia cells with the BIM variation under a microscope. Such cells often don’t respond well to imatinib, a common type of drug used to treat the disease, but when an MCL-1 inhibitor is added, treatment is more effective with more cancer cells being killed. Credit: Duke-NUS Medical School Scientists from Duke-NUS Medical...
Tag: <span>Leukemia</span>
Post
Promising cell therapy offers hope for relapsed or refractory T-cell leukemia
Antileukemia activity of anti-CD7 PEBL-CAR T cells. Credit: Nature Medicine (2024). DOI: 10.1038/s41591-024-03228-8 A new cell therapy, targeting CD7 in leukemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have exhausted all standard treatment options. Published in the journal Nature Medicine on 3 September 2024, the study highlights the effectiveness of a new chimeric...
Post
Blood cancers: Expert explains what you need to know
September 30, 2024 by Robin Foster Blood cancer is not a diagnosis anyone wants to receive, but understanding the different types of this disease and how best to catch them early is essential, one expert says. First, blood cancers are far more common than you might think: One person in the United States is diagnosed...
Post
Study provides new insights into fighting leukemia by targeting its stem cells
JULY 24, 2024 by University of Geneva Credit: Unsplash/CC0 Public DomainAcute myeloid leukemia (AML) is the most common blood and bone marrow cancer in adults. Caused by an increase in immature cells that rapidly destroy and replace healthy blood cells (red and white blood cells and platelets), AML is lethal in half of those affected...
Post
A new drug target identified for diseases associated with leukemia-causing virus
JULY 22, 2024 by Christine Yu, Pennsylvania State University KDR inhibition induces autophagic/lysosomal degradation of Tax. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-49737-5A team of researchers from Penn State College of Medicine found a new target for treating diseases associated with human T-cell leukemia virus type 1 (HTLV-1). They determined that blocking a class of enzymes...
Post
Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia
MAY 31, 2024 by University of Texas M. D. Anderson Cancer Center Credit: Unsplash/CC0 Public Domain Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two studies today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings highlight strong remission and response rates and offer...
Post
Scientists devise novel strategy to seek and destroy leukemia stem cells
by City of Hope National Medical Center Type II interferon (IFNy), a substance produced by immune cells, disrupts the leukemia stem cells’ ability to divide and spread cancer. However, IFNy also stimulates CD38, a protein that suppresses the immune cells’ ability to mount a response against infection. To overcome this challenge, City of Hope researchers designed...
Post
Team discovers how to predict whether patients with leukemia will be sensitive to epigenetic drugs
by Josep Carreras Leukaemia Research Institute Credit: Cancer Research Communications (2024). DOI: 10.1158/2767-9764.CRC-23-0389Alterations in the chemical modifications that control gene expression, known as epigenetics, have proven to be one of the most characteristic properties of all human tumors. This realization has generated the development of intense pharmacological research to find drugs that act at this level...
Post
Leukemia rash pictures and symptoms
Symptoms of leukemia can include skin-related issues, such as a rash or bruising. Petechiae and purpura can be the first sign of leukemia a person may notice. When a person has leukemia, their body produces too many white blood cells. As they continue to grow in number, they crowd out the other cells in the...
Post
Researchers discover compound that fights leukemia and lymphoma
by University of Texas at El Paso Renato Aguilera, Ph.D., a professor in the Department of Biological Sciences at The University of Texas at El Paso, is the principal investigator on a project that identified a novel pharmaceutical compound that successfully kills leukemia and lymphoma cancer cells, potentially paving the way for new forms of therapy....